Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.
Kriangkrai TawinpraiTaweegrit SiripongboonsittiThachanun PorntharukchareonKasiruck WittayasakNawarat ThonwirakKamonwan SoonklangGaidganok SornsamdangChirayu AuewarakulNithi MahanondaPublished in: Expert review of vaccines (2022)
A third vaccination with the heterologous vaccine, BBIBP-CorV, AZD1222, or BNT162b2, can elicit a robust immune response, without serious adverse events in participants fully vaccinated with the CoronaVac vaccine.